PET: The merging of biology and imaging into molecular imaging

Journal of Nuclear Medicine

Volumn 41, Issue 4, 2000, Pages 661-681

  Phelps, Michael E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Cardiovascular disease; Imaging gene expression; Molecular imaging; Neurological disease; PET

Indexed keywords

ADENOSINE TRIPHOSPHATE; DEOXYGLUCOSE; DNA; FLUORODEOXYGLUCOSE F 18; MESSENGER RNA; NUCLEOTIDE; PROTEIN; RADIOISOTOPE;

ARTICLE; AUTORADIOGRAPHY; BRAIN MAPPING; BRAIN METABOLISM; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; GENE EXPRESSION; HUMAN; IMAGING; MALIGNANT NEOPLASTIC DISEASE; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ANIMALS; CORONARY DISEASE; DIAGNOSTIC IMAGING; GENE EXPRESSION; HUMANS; HUNTINGTON DISEASE; MICE; NEOPLASMS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034126959     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Phelps M, Hoffman E, Mullani N, Ter-Pogossian M. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med. 1975;16:210-224.
2. Phelps M, Hoffman E, Mullani N, Higgins C, Ter-Pogossian M. Design considerations for a positron emission transaxial tomograph (PETT III). IEEE Trans Biomed Eng. 1976;NS-23:516-522.
3. Hoffman E, Phelps M, Mullani N, Higgins C, Ter-Pogossian M. Design and performance characteristics of a whole body transaxial tomograph. J Nucl Med. 1976;493-503.
4. Cho Z, Chan J, Eriksson L. Circular ring transverse axial positron camera for 3-dimensional reconstruction of radionuclide distribution IEEE Trans Nucl Sci. 1976;NS-23:613-622.
5. Derenzo S, Budinger T, Cahoon J. High resolution computed tomography of positron emitters. IEEE Nucl Sci. 1977;NS-24:544-558.
6. 14C) deoxyglucose method for the measurement of local glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28:897-916.
7. Woodward GE, Hudson MT. The effect of 2-deoxy-D-glucose in glycolysis and respiration of tumor and normal tissues. Cancer Res. 1954;14:599-605.
8. 14C-2-deoxy-2-fluoro-D-glucose. J Labeled Compds Radiopharmacol. 1978;14:175-183.
9. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371-388.
10. 18F)fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44: 117-127.
11. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin C, Kuhl DE. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol. 1980;238:E69-E82.
12. Sokoloff L. Circulation and energy metabolism of the brain. In: Siegel G, Agranoff B, Albers RW, Molinoff P, eds. Basic Neurochemistry, 4th ed., New York, NY: Raven; 1989:565-590.
13. Ernst RL, Hay JW. The U.S. economic and social costs of Alzheimer's disease revisited. Am J Pub Health. 1994;814:1261-1264.
14. National Institute on Aging. Progress Report on Alzheimer's Disease. NIH Publication 96-4137. Bethesda, MD: National Institute on Aging; 1996.
15. Dura R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology. 1986;36:879-887.
16. Mazziotta JC, Frackowiak RSJ, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Semin Nucl Med. 1992;22: 233-246.
17. Herholz K. FDG PET and differential diagnosis of dementia. Alzheim Dis Assoc Disord. 1995;9:6-16.
18. Silverman DHS, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia: sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. Clin Positron Imaging. 1999;2:119-130.
19. Silverman DHS, Chang CY, Cummings J, et al. Neuroimaging in evaluation of dementia: regional brain metabolism and long-term clinical outcomes. Ann Intern Med. 2000: in press.
20. Mazziotta JC, Phelps ME, Huang SC, et al. Cerebral glucose utilization reductions in clinically asymptomatic subjects at risk for Huntington's disease. N Engl J Med. 1987;316:357-362.
21. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273:942-947.
22. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. N Engl J Med. 1996;334:752-758.
23. Schelbert HR. The usefulness of positron emission tomography. Curr Probl Cardiol. 1998;2:69-120.
24. Ausma J, Thonae F, Dispersyn GD, et al. Dedifferentiated cardiomyocytes from chronic hibernating myocardium are ischemia-tolerant. Mol Cell Biochem. 1998;186:159-168.
25. Weber G. Enzymology of cancer cells. N Engl J Med. 1977;296:541-551.
26. White A, Handler P, Smith E. Principles of Biochemistry, 5th ed. New York, NY: McGraw-Hill; 1973:441.
27. Dahlbom M, Hoffman E, Hoh C, et al. Evaluation of a positron emission tomography scanner (PET) for whole body imaging. J Nucl Med. 1992;33:1191-1199.
28. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small-cell lung cancer by whole-body PET imaging. Ann Thorac Surg. 1995;60:1573-1582.
29. Changlai SP, Schiepers C, Blatt S A, et al. The impact of whole body FDG PET on staging of lung cancer [abstract]. J Nucl Med. 1999;40(suppl):56P.
30. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET in clinical oncology. Nucl Med Biol. 1996;23:737-743.
31. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803-809.
32. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171: 21-26.
33. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg. 1994;81:1666-1670.
34. 18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg. 1996;131:703-707.
35. Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with F-18-fluorodeoxygluose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503-511.
36. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol. 1997;4:613-620.
37. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 1996;6:325-329.
38. 18F-fluorodeoxyglucose positron emission tomography. Cancer. 1998;82:1664-1671.
39. Stumpe KDM, Urhinell M, Steingert HC, et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med. 1998;25:721-728.
40. Moog F, Bangerter M, Diedrichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998;206:475-481.
41. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med. 1996;37:1428-1436.
42. Gambhir SS, Shepherd JE, Shah BD, et al. An analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol. 1998;16: 2113-2125.
43. Cherry SR, Shao Y, Silverman RW, et al. MicroPET: a high resolution PET scanner for imaging small animals. IEEE Trans Nucl Sci. 1997;44:1109-1113.
44. Chatziioannou AF, Cherry SR, Shao Y, et al. Performance evaluation of microPET: a high resolution lutetium oxyorthosilicate PET scanner for animal imaging. J Nucl Med. 1999;40:1164-1175.
45. Casey ME, Eriksson L, Schmand M, et al. Investigation of LSO crystals for high spatial resolution positron emission tomography. IEEE Trans Nucl Sci. 1997;44: 1109-1113.
46. Qi J, Leahy RM, Cherry SR, Chatziioannou A, Farquhar TH. High resolution 3D Bayesian image reconstruction using the microPET small animal scanner. Phys Med Biol. 1998;43:1001-1013.
47. Cherry SR, Shao Y, Slates RB, Wilcut E, Chatziioannou AF, Dahlbom M. MicroPET II: design of a 1 mm resolution PET scanner for small animal imaging [abstract]. J Nucl Med. 1999;40(suppl):75P.
48. Phelps ME, Kuhl DE, Mazziotta JC. Metabolic mapping of the brain's response to visual stimulation: studies in humans. Science. 1981;211:1445-1448.
49. 18F) fluorodeoxyglucose technique. Science. 1981;212:678-680.
50. Fox PT, Mintun M, Raichle M, et al. Mapping human visual cortex with positron emission tomography. Nature. 1986;323:806-809.
51. Ogawa S, Tank DW, Menon R, et al. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci USA. 1992;89:5951-5955.
52. Wu AM, Yazuki PJ, Tsai S-W, et al. MicroPET imaging of tumors in a murine model utilizing a Cu-64 radiolabeled genetically engineered anti-CEA antibody fragment [abstract]. J Nucl Med. 1999;40(suppl):80P.
53. Rubins DJ, Melega WP, Cherry SR, Lacan G. Quantitation of striatal dopamine transporter in the rat with [C-11]WIN 25,428 and microPET [abstract]. J Nucl Med. 1999;40(suppl):261P.
54. Gambhir SS, Barrio JR, Herschman HR, Phelps ME. Imaging expression: principles and assays. J Nucl Card. 1999;6:219-233.
55. Pan D, Gambhir SS, Toyokuni T, et al. Rapid synthesis of a 5′-fluorinated oligodeoxynucleotide: a model antisense probe for use in imaging with positron emission tomography (PET). Bioorg Med Chem Lett. 1998;8:1317-1320.
56. Loke SL, Stein CA, Zhang XH, et al. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA. 1989;86:7595-7599.
57. Wu-Pong S, Weiss TL, Hunt AC. Antisense c-myc oligonucleotide cellular uptake and activity. Antisense Res Dev. 1994;4:155-163.
58. Crooke ST. Progress in antisense therapeutics. Hematol Pathol. 1995;9:59-72.
59. Tavitian B, Terrazzino S, Kuhnast B, et al. In vivo imaging of oligonucleotides with positron emission tomography. Nature Med. 1998;4:467-471.
60. Misteli T, Spector D. Applications of the green fluorescent protein in cell biology and biotechnology. Nat Biotechnol. 1997;15:961-964.
61. Jacobs WR, Barletta RG, Udani R, et al. Rapid assessment of drug susceptibilities of mycobacterium tuberculosis by means of luciferase reporter phages. Science. 1993;260:819-822.
62. 19F]fluoroethyl)spiperone, a potent dopamine antagonist: synthesis, structural analysis and in vivo utilization in humans. J Appl Rad Isot. 1990;41: 113-129.
63. Tjuvajev JG, Stockhammer G, Desai R, et al. Imaging the expression of transfected genes in vivo. Cancer Res. 1995;55:6126-6132.
64. Tjuvajev JG, Finn R, Watanabe K, et al. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res. 1996;56:4087-4095.
65. Tjuvajev JG, Avril N, Safer M, et al. Quantitative PET imaging of HSV1-TK gene expression with [1-124]FIAU [abstract]. J Nucl Med. 1997;38(suppl):239P.
66. Barrio JR, Namavari M, Phelps ME, et al. Regioselective fluorination of substituted guanines with dilute F2: a facile entry of 8-fluoroguanine derivatives. J Organic Chem. 1996;61:6084-6085.
67. Gambhir SS, Barrio JR, Wu L, et al. Imaging of adenoviral directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med. 1998;39:2003-2011.
68. Gambhir SS, Barrio JR, Phelps ME, et al. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci USA. 1999;96:2333-2338.
69. 18F]fluoroguanine derivatives: in vivo probes for imaging gene expression with PET. Nucl Med Biol. 2000: in press.
70. Gambhir SS, Barrio JR, Herschman HR, Phelps ME. Assays for non-invasive imaging of reporter gene expression. Nucl Med Biol. 1999;26:481-490.
71. Gambhir SS, Barrio JR, Iyer M, et al. In vivo validation of PET reporter gene/reporter probe assay for herpes simplex virus type 1 thymidine kinase with 8-[F-18]-fluoropenciclovir [abstract]. J Nucl Med. 1999;40(suppl):25P-26P.
72. 18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol. 1998;25: 175-180.
73. MacLaren DC, Gambhir SS, Satyamurthy N, et al. Repetitive non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther. 1999;6:785-791.
74. Gordon EM, Barrett RW, Dower WJ, et al. Applications of combinatorial technologies to drug discovery: part 2. Combinatorial organic synthesis, library screening strategies, and future directions. J Med Chem. 1994;10:1385-1401.
75. Satyamurthy N, Barrio JR, Phelps ME. Electronic generators for production of positron-emitter labeled radiopharmaceuticals: where would PET be without them? Clin Positron Imaging. 1999;2:233-254.
76. Shao Y, Cherry SR, Farahani K, et al. Development of a PET detector system compatible with MRI/NMR systems. IEEE Trans Nucl Sci. 1997;44:1167-1171.
77. Beyer T, Townsend DT, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000: in press.
78. Patton JA, Delbeke D, Sandler MP. Image fusion using integrated dual-head coincidence camera with x-ray tube based attenuation maps. J Nucl Med. 2000: in press.